IBI355

DRUG3 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd.

Conditions

HealthyHealthy SubjectsPrimary Sjögren's Syndrome

Phase 1

Safety and Tolerance Study of IBI355 in Health Volunteers

CompletedNCT06110338

Innovent Biologics (Suzhou) Co. Ltd.Healthy Subjects

Start: 2023-10-30End: 2024-09-23Updated: 2024-10-21

Safety and Tolerability of IBI355 in Healthy Volunteers

CompletedNCT06416787

Innovent Biologics (Suzhou) Co. Ltd.Healthy

Start: 2024-05-20End: 2025-04-02Updated: 2025-05-21

Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome

CompletedNCT06484855

Innovent Biologics (Suzhou) Co. Ltd.Primary Sjögren's Syndrome

Start: 2024-07-14End: 2025-07-25Updated: 2025-09-15